Summary
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Araim Pharmaceuticals, Inc.
CSL Limited
GeNeuro SA
Mitsubishi Tanabe Pharma Corporation
Neuren Pharmaceuticals Limited
Pfizer Inc.
Pharnext SAS
Polyneuron Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Sanofi
Shire Plc
Teijin Pharma Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral Neuropathy (Sensory Neuropathy) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 10
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 11
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 12
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 16
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 17
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 18
Araim Pharmaceuticals, Inc. 18
CSL Limited 19
GeNeuro SA 20
Mitsubishi Tanabe Pharma Corporation 21
Neuren Pharmaceuticals Limited 22
Pfizer Inc. 23
Pharnext SAS 24
Polyneuron Pharmaceuticals AG 25
RegeneRx Biopharmaceuticals, Inc. 26
Sanofi 27
Shire Plc 28
Teijin Pharma Limited 29
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(baclofen + naltrexone + sorbitol) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
(hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
aminoquinol - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
cibinetide - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
EDE-1204 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
fingolimod hydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GL-2045 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GNbAC-1 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
immune globulin (human) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
immune globulin (human) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
immune globulin (human) - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
NNZ-2591 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
PN-1007 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
RGN-352 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
SAR-184841 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Synthetic Peptides for Peripheral Neuropathy - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects 77
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products 79
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 80
Featured News & Press Releases 80
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 80
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 80
Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 80
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 81
Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 82
May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 83
Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86
List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016 9
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 18
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H2 2016 19
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H2 2016 20
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 21
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2016 22
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2016 23
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pharnext SAS, H2 2016 24
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H2 2016 25
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 26
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H2 2016 27
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Shire Plc, H2 2016 28
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2016 77
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H2 2016 78
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2016 79
List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016 9
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Targets, H2 2016 32
Number of Products by Stage and Targets, H2 2016 32
Number of Products by Mechanism of Actions, H2 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Routes of Administration, H2 2016 36
Number of Products by Stage and Routes of Administration, H2 2016 36
Number of Products by Molecule Types, H2 2016 38
Number of Products by Stage and Molecule Types, H2 2016 38
